Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. 12042668 2002
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. 17136762 2007
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 Biomarker group CTD_human 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. 17136762 2007
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group BEFREE Association of SRD5A2 genotype and pathological characteristics of prostate tumors. 10749132 2000
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. 12771801 2003
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 Biomarker group LHGDN Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. 16018939 2005
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 AlteredExpression group LHGDN Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. 12949937 2003
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 AlteredExpression group LHGDN Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. 15538746 2005
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 Biomarker group BEFREE DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. 26332453 2015
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. 12746845 2003
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. 15326487 2004
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN It is therefore possible that polymorphisms in the androgen synthesis gene 5alpha-reductase type II (SRD5A2) may be involved in the progression of prostate tumors. 19215786 2009
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 Biomarker group BEFREE It is therefore possible that polymorphisms in the androgen synthesis gene 5alpha-reductase type II (SRD5A2) may be involved in the progression of prostate tumors. 19215786 2009
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. 17448593 2007
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. 18469342 2008
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. 12712437 2003
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians. 17376218 2008
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. 12210487 2002
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. 15477877 2004
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. 17823934 2007
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 Biomarker group CTD_human SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. 17823934 2007
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 Biomarker group CTD_human Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. 16998812 2006
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 GeneticVariation group LHGDN The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. 16039774 2005
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 Biomarker group CTD_human The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. 18306354 2008
Entrez Id: 6716
Gene Symbol: SRD5A2
SRD5A2
0.400 AlteredExpression group LHGDN The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. 12738739 2003